These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

634 related articles for article (PubMed ID: 32955172)

  • 21. Unmasking of oestrogen-dependent changes in left ventricular structure and function in aged female rats: a potential model for pre-heart failure with preserved ejection fraction.
    Bustamante M; Garate-Carrillo A; R Ito B; Garcia R; Carson N; Ceballos G; Ramirez-Sanchez I; Omens J; Villarreal F
    J Physiol; 2019 Apr; 597(7):1805-1817. PubMed ID: 30681142
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiac diastolic and autonomic dysfunction are aggravated by central chemoreflex activation in heart failure with preserved ejection fraction rats.
    Toledo C; Andrade DC; Lucero C; Arce-Alvarez A; Díaz HS; Aliaga V; Schultz HD; Marcus NJ; Manríquez M; Faúndez M; Del Rio R
    J Physiol; 2017 Apr; 595(8):2479-2495. PubMed ID: 28181258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Large animal models to study effectiveness of therapy devices in the treatment of heart failure with preserved ejection fraction (HFpEF).
    Fisher SM; Murally AR; Rajabally Z; Almas T; Azhar M; Cheema FH; Malone A; Hasan B; Aslam N; Saidi J; O'Neill J; Hameed A
    Heart Fail Rev; 2024 Jan; 29(1):257-276. PubMed ID: 37999821
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heart failure with preserved ejection fraction: current management and future strategies : Expert opinion on the behalf of the Nucleus of the "Heart Failure Working Group" of the German Society of Cardiology (DKG).
    Tschöpe C; Birner C; Böhm M; Bruder O; Frantz S; Luchner A; Maier L; Störk S; Kherad B; Laufs U
    Clin Res Cardiol; 2018 Jan; 107(1):1-19. PubMed ID: 29018938
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.
    Paulus WJ; Tschöpe C
    J Am Coll Cardiol; 2013 Jul; 62(4):263-71. PubMed ID: 23684677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simvastatin Attenuates Cardiac Fibrosis under Pathophysiological Conditions of Heart Failure with Preserved Left Ventricular Ejection Fraction by Inhibiting TGF-β Signaling.
    Marunouchi T; Matsumura K; Fuji E; Iwamoto A; Tanonaka K
    Pharmacology; 2024; 109(1):43-51. PubMed ID: 38016432
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myocardial expression of somatotropic axis, adrenergic signalling, and calcium handling genes in heart failure with preserved ejection fraction and heart failure with reduced ejection fraction.
    D'Assante R; Arcopinto M; Rengo G; Salzano A; Walser M; Gambino G; Monti MG; Bencivenga L; Marra AM; Åberg DN; De Vincentiis C; Ballotta A; Bossone E; Isgaard J; Cittadini A
    ESC Heart Fail; 2021 Apr; 8(2):1681-1686. PubMed ID: 33512777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The role of inflammation in heart failure with preserved ejection fraction].
    Zhang Q; Chen YE; Zhu XX; Wang X; Qu AJ
    Sheng Li Xue Bao; 2023 Jun; 75(3):390-402. PubMed ID: 37340648
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insight into the Pro-inflammatory and Profibrotic Role of Macrophage in Heart Failure With Preserved Ejection Fraction.
    Shen JL; Xie XJ
    J Cardiovasc Pharmacol; 2020 Sep; 76(3):276-285. PubMed ID: 32501838
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Galectin-3 in heart failure with preserved ejection fraction.
    de Boer RA; Edelmann F; Cohen-Solal A; Mamas MA; Maisel A; Pieske B
    Eur J Heart Fail; 2013 Oct; 15(10):1095-101. PubMed ID: 23650131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.
    Shah AM; Cikes M; Prasad N; Li G; Getchevski S; Claggett B; Rizkala A; Lukashevich I; O'Meara E; Ryan JJ; Shah SJ; Mullens W; Zile MR; Lam CSP; McMurray JJV; Solomon SD;
    J Am Coll Cardiol; 2019 Dec; 74(23):2858-2873. PubMed ID: 31806129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction: Association With Baseline Disease Severity and Subsequent Outcome.
    Schelbert EB; Fridman Y; Wong TC; Abu Daya H; Piehler KM; Kadakkal A; Miller CA; Ugander M; Maanja M; Kellman P; Shah DJ; Abebe KZ; Simon MA; Quarta G; Senni M; Butler J; Diez J; Redfield MM; Gheorghiade M
    JAMA Cardiol; 2017 Sep; 2(9):995-1006. PubMed ID: 28768311
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthetic growth hormone-releasing hormone agonist ameliorates the myocardial pathophysiology characteristic of heart failure with preserved ejection fraction.
    Dulce RA; Kanashiro-Takeuchi RM; Takeuchi LM; Salerno AG; Wanschel ACBA; Kulandavelu S; Balkan W; Zuttion MSSR; Cai R; Schally AV; Hare JM
    Cardiovasc Res; 2023 Feb; 118(18):3586-3601. PubMed ID: 35704032
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics.
    Abudureyimu M; Luo X; Wang X; Sowers JR; Wang W; Ge J; Ren J; Zhang Y
    J Mol Cell Biol; 2022 Sep; 14(5):. PubMed ID: 35511596
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypertension as a Road to Treatment of Heart Failure with Preserved Ejection Fraction.
    Hicklin HE; Gilbert ON; Ye F; Brooks JE; Upadhya B
    Curr Hypertens Rep; 2020 Sep; 22(10):82. PubMed ID: 32880741
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heart Failure with Preserved Ejection Fraction and Future Pharmacological Strategies: a Glance in the Crystal Ball.
    Tschöpe C; Van Linthout S; Kherad B
    Curr Cardiol Rep; 2017 Aug; 19(8):70. PubMed ID: 28656481
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiac magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities.
    Quarta G; Gori M; Iorio A; D'Elia E; Moon JC; Iacovoni A; Burocchi S; Schelbert EB; Brambilla P; Sironi S; Caravita S; Parati G; Gavazzi A; Maisel AS; Butler J; Lam CSP; Senni M
    Eur J Heart Fail; 2020 Jul; 22(7):1065-1075. PubMed ID: 32654354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diffuse right ventricular fibrosis in heart failure with preserved ejection fraction and pulmonary hypertension.
    Patel RB; Li E; Benefield BC; Swat SA; Polsinelli VB; Carr JC; Shah SJ; Markl M; Collins JD; Freed BH
    ESC Heart Fail; 2020 Feb; 7(1):253-263. PubMed ID: 31903694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug Targets for Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach and Review of Contemporary Clinical Trials.
    Patel RB; Shah SJ
    Annu Rev Pharmacol Toxicol; 2019 Jan; 59():41-63. PubMed ID: 30296895
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent advances in mechanistic studies of heart failure with preserved ejection fraction and its comorbidities-Role of microRNAs.
    Li X; Sun M; Wang Z; Sun S; Wang Y
    Eur J Clin Invest; 2024 Mar; 54(3):e14130. PubMed ID: 38071416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.